Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.

Background: To date, there are no available factors to predict the outcome after multiple sclerosis relapse.

Aim: To investigate factors that may be useful for predicting response to methylprednisolone treatment, following a relapse of multiple sclerosis (MS).

Methods: The study included 48 MS patients enrolled in a double-blind multicenter trial to receive intravenous versus oral high-dose methylprednisolone treatment.